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Task sharing for the care of severe mental
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Abstract
Background: Task sharing mental health care through integration into primary health care (PHC) is advocated as a
means of narrowing the treatment gap for mental disorders in low-income countries. However, the effectiveness,
acceptability, feasibility and sustainability of this service model for people with a severe mental disorder (SMD) have
not been evaluated in a low-income country.
Methods/Design: A randomised, controlled, non-inferiority trial will be carried out in a predominantly rural area of
Ethiopia. A sample of 324 people with SMD (diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder or
major depressive disorder) with an ongoing need for mental health care will be recruited from 1) participants in a
population-based cohort study and 2) people attending a psychiatric nurse-led out-patient clinic. The intervention
is a task-sharing model of locally delivered mental health care for people with SMD integrated into PHC delivered
over 18 months. Participants in the active control arm will receive the established and effective model of specialist
mental health care delivered by psychiatric nurses at an out-patient clinic within a centrally located general
hospital. The hypothesis is that people with SMD who receive mental health care integrated into PHC will have a
non-inferior clinical outcome, defined as a mean symptom score on the Brief Psychiatric Rating Scale, expanded
version, of no more than six points higher, compared to participants who receive the psychiatric nurse-led service,
after 12 months. The primary outcome is change in symptom severity. Secondary outcomes are functional status,
relapse, service use costs, service satisfaction, drop-out and medication adherence, nutritional status, physical health
care, quality of care, medication side effects, stigma, adverse events and cost-effectiveness. Sustainability and cost-
effectiveness will be further evaluated at 18 months. Randomisation will be stratified by health centre catchment
area using random permuted blocks. The outcome assessors and investigators will be masked to allocation status.
Discussion: Evidence about the effectiveness of task sharing mental health care for people with SMD in a rural,
low-income African country will inform the World Health Organisation’s mental health Gap Action Programme to
scale-up mental health care globally.
Trial registration: NCT02308956 (ClinicalTrials.gov). Date of registration: 3 December 2014.
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Background
Task-sharing care to alleviate the burden of severe
mental disorders in Africa
The unmet need for mental health care is high in all coun-
tries of the world but is particularly acute in low-income
countries [1]. Ethiopia is typical of most low-income
countries, with fewer than 10 % of people with severe
mental disorders (SMD) receiving mental health care [2].
SMDs are predominantly psychotic disorders that are
chronic or recurrent, have a substantial impact on affected
people and their families and rank highly in terms of dis-
ease burden [3, 4]. The lack of treatment or inadequate
treatment for SMDs is associated with a high level of
suffering and disability [5–7], family burden [8], stigma,
discrimination and human rights abuses [9, 10], out-of-
pocket costs and opportunity costs to affected individuals
and their families [11], poor physical health and under-
nutrition [12], and premature mortality [13, 14].
Centralised services, a critical shortage of specialist
mental health workers and an absence of mental health
care in general health care settings are the main causes
of this large treatment gap for SMDs in the low-income
countries of sub-Saharan Africa [15]. In Ethiopia, outside
of the capital city, Addis Ababa, mental health services
are largely limited to regional cities, with most care pro-
vided within psychiatric nurse-led, hospital-based clinics
[16, 17]. The majority of Ethiopia’s population, however,
lives in rural areas [18]. In order to improve access to
mental health care, a ‘task sharing’ approach is required.
The concept of task sharing is similar to that of task
shifting, defined as delegating tasks to existing or new
cadres with either less training or narrowly tailored
training [19, 20] but also recognises the ongoing role of
specialists. For mental health care, it is advocated that
primary care and general health care workers be given
brief training to deliver circumscribed aspects of care for
prioritised mental, neurological and substance-use disor-
ders, with the support of specialist mental health
workers who provide supervision, consultation, refresher
training and referral [21].
In a series of systematic reviews conducted by the
World Health Organisation (WHO), packages of mental
health interventions were identified (detailed in the
Mental Health Gap Project Intervention Guide: mhGAP-
IG) that can be delivered in the PHC setting and have
demonstrated effectiveness for a range of mental,
neurological and substance use disorders [22]. The
task sharing model of mental health care integrated
into PHC, proposed by WHO in mhGAP, is expected
to be more affordable and accessible for the majority
of people with SMD in low-income countries. By lo-
cating mental health care in PHC, the potential exists
for people with SMD to receive improved physical
health care [23].
The need for trials of task-sharing interventions for
mental health care
Despite the potential advantages of task-sharing mental
health care, little is known about how different aspects
of the care needed by people with SMDs can be safely
and effectively transferred to the PHC setting in a rural,
low-income country setting such as Ethiopia. In a recent
review of task-sharing approaches to health care in
LMICs, evidence was offered that task sharing can im-
prove the productive efficiency of services (that is, the
greatest amount of care at a given quality and a given
cost), although challenges regarding quality, safety and
sustainability were also identified [20]. Most of the iden-
tified evaluations of task sharing were in the fields of
surgery, obstetrics and HIV care, and few employed ran-
domised, controlled trial designs. With respect to mental
health care in particular, little is known about the ac-
ceptability of task sharing to service users or PHC
workers [24] or the feasibility and sustainability of such
a model [25, 26]. Uncertainty also exists as to whether
stigma will be greater or lesser in a separate psychiatric
clinic that is further from the place of residence com-
pared to an integrated service that is in the person’s lo-
cality. The paucity of clinical trials of interventions for
SMD in Africa has been highlighted, concluding that
there is a pressing need for high-quality evidence from
pragmatic trials with adequate follow-up periods [27]. In
a consensus exercise conducted to set priorities for glo-
bal mental health, the integration of mental health care
into primary care was within the top five issues to be ad-
dressed to improve scale-up and impact of mental health
care [28]. The TaSCS trial, therefore, addresses an im-
portant evidence gap and has the potential to inform
policy initiatives to scale-up mental health care in the
African region and beyond.
Context of the TaSCS trial
The Africa Focus on Intervention Research for Mental
health (AFFIRM) programme was established in 2011
with the objective of investigating strategies for narrow-
ing the treatment gap for mental disorders in sub-
Saharan Africa [29]. AFFIRM connects six countries of
sub-Saharan Africa - Ethiopia, Ghana, Malawi, South
Africa, Uganda and Zimbabwe - and is engaged in devel-
oping contextualised trial outcome measures [30], build-
ing capacity for intervention research, developing a
collaborative network and conducting trials of task-
sharing interventions in South Africa [31] and Ethiopia.
Ethiopia was selected as the setting for a task-sharing
trial for care of people with SMD for several reasons: 1)
the Federal Ministry of Health of Ethiopia is just begin-
ning to scale up mental health care through integration
into PHC and has prioritised care for people with SMD
[16]; 2) a well-described, population-based cohort of
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persons with standardised, clinician-defined diagnoses of
SMD in Butajira, Ethiopia [2], provides a more relevant
sample within which to nest a trial to inform scale-up
than the usual facility-based samples; and 3) Ethiopia is
a predominantly rural, low-income African country,
which provides an important test case for WHO’s
mhGAP.
Rationale for a non-inferiority trial
In this trial, we propose to investigate the non-inferiority
of a task-sharing model of mental health care in PHC
compared to the established alternative service model
within Ethiopia: a less accessible (more centralised), but
more specialist, psychiatric nurse-led model of care. The
psychiatric nurse-led model of care has been demon-
strated to be acceptable and associated with improved
clinical outcomes for people with SMD engaged in the
service in this sample in Butajira, Ethiopia, thus making
this an appropriate comparison model [2]. Task-sharing
mental health care in PHC in Ethiopia is expected to
allow more mental health care to be provided for the
same cost compared to expanding specialist mental
health care and is, therefore, of critical importance in
addressing the high treatment gap. However, the import-
ant policy question for Ethiopia, and other low-income
countries, is to establish whether or not the new task-
sharing model for mental health care in PHC is good
enough to meet the needs of people with SMD. At
present, no evidence exists to inform this policy ques-
tion. We will therefore conduct a non-inferiority trial in
order to evaluate whether or not task sharing is at least
no worse than specialist mental health care across a
range of outcomes.
Objectives
The overall objective of the TaSCS trial is to determine
the acceptability, affordability, effectiveness and sustain-
ability of mental health care for people with SMD, deliv-
ered by trained and supervised non-specialist PHC
workers compared to an existing psychiatric nurse-led
service.
The specific objectives are as follows:
1. To determine the effectiveness and cost-effectiveness
of task-sharing mental health care for people with
SMD with PHC, compared to psychiatric nurse-led
mental health care, on the primary outcome measure
of symptom severity and on a series of secondary
outcome measures.
2. To examine factors influencing the implementation
of the task sharing intervention and future scale-up,
by examining the feasibility, sustainability, quality
and safety, and by qualitative exploration of the
experience of task sharing from the perspectives of
service users, PHC workers and health service
managers.
Hypothesis
People with SMD who receive mental health care that is
task shared with PHC will have a non-inferior clinical
outcome, defined as a difference in the mean symptom
score on the Brief Psychiatric Rating Scale, expanded
version (BPRS-E) [32], of no more than six points higher,
compared to people with SMD who receive a psychiatric
nurse-led model of mental health care, after 12 months.
Methods
Trial design
The study is an individual level, randomised, controlled
non-inferiority trial.
Setting
The study will be conducted in the Meskan and Mareko
districts of the Gurage Zone and the Silti Zone of the
Southern Nations, Nationalities and People’s region,
Ethiopia. The Meskan and Mareko districts have an esti-
mated population of 159,884 and 63,436, respectively
[18]. The area is predominantly rural. Most inhabitants
are farmers, growing maize for subsistence and chili
pepper and khat (an amphetamine-like substance) as
cash crops. The main town is Butajira, located around
130 km from the capital city, Addis Ababa. Road infra-
structure has expanded in the last few years, but the ma-
jority of the population do not live close to all-weather
roads. The population is prone to food insecurity and
was affected by famine in 1974, 1985, 1999 and 2003.
Mental health research activities have been carried out
in the Butajira area for the last 18 years.
Within the study site, one government general hospital
is present, located in the town of Butajira. The hospital
is staffed by general physicians, a surgeon and obstetri-
cian, as well as health officers (3 to 4 years of training at
BSc level) and nursing staff (2 to 3 years training at BSc
and Diploma level). There are 13 health centres in the
rural areas surrounding the town of Butajira. Health
centres provide PHC services comprising preventive
health care, treatment of acute illness and delivery ser-
vices, but no in-patient care. Health centres are staffed
by health officers and general nurses. Each health centre
is linked to five satellite health posts, staffed by two
community health extension workers and located within
walking distance of most residents (most with 5 to
10 km). Health extension workers are all women from
the local area who have completed high school (grade 10)
and a year of training in health promotion and illness pre-
vention. The health extension workers form an interface
between the PHC system and the community, dividing
their time between house-to-house visits, community
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awareness-raising activities and a limited range of health
post-based primary care services.
Participants
Study participants will be recruited from two sources:
(1) the population-based Butajira SMD cohort study
sample and (2) the Butajira psychiatric nurse-led out-
patient clinic.
Butajira SMD cohort
The Butajira SMD population-based cohort was estab-
lished between 1998 and 2001 [5]. People with possible
SMD were identified in two ways: (1) through a house-
to-house survey covering 68,378 people using the Com-
posite International Diagnostic Interview (CIDI) [33] as
a screening tool, and (2) through community key infor-
mants, who had been trained using vignettes describing
typical presentations of SMD [34]. All potential cases
were invited for a second phase clinician assessment
conducted by an Ethiopian physician using the Schedule
for Clinical Assessment in Neuropsychiatry (SCAN)
[35]. Of the 2285 SCAN assessments conducted, 844
people were diagnosed as having SMD and recruited
into the cohort. Incident cases (n = 75) from the geo-
graphical catchment area over the next 2 years also
underwent confirmatory diagnosis with SCAN and were
recruited into the cohort, giving a total of 919 people
with SMD: 359 with schizophrenia or schizoaffective dis-
order, 345 with bipolar disorder and 215 with severe
major depressive disorder [13]. After 10 years (2011/
2012) of follow-up, a clinician assessment was carried
out using the Longitudinal Interval Follow-up Evaluation
(LIFE) chart [36]. At that time, loss to follow-up from
the cohort was as follows: 121 had died, 112 had refused
to continue study assessments, 15 were vagrant and 70
had changed address and were not contactable. Study
participants were more likely to be lost to follow-up if
they were male, unmarried, had a diagnosis of schizo-
phrenia and were more severely unwell at baseline, al-
though the differences were small. However, loss to
follow-up was not associated with age, literacy or em-
ployment status. The Butajira SMD cohort is one of the
very few population-based studies of SMD from a LMIC.
Even with the potential attrition bias, the Butajira SMD
cohort offers a unique opportunity to obtain a sample
that is free from the substantial selection bias associated
with facility-based recruitment and is potentially more
generalisable to people with SMD, who would access
task-shared mental health care in PHC.
Butajira hospital psychiatric out-patient clinic
In Butajira, the general hospital has a psychiatric out-
patient clinic run by psychiatric nurses. At present this
clinic is the only mental health care available within the
districts covered by the TaSCS trial, as is the case in
most of Ethiopia [37]. Since completion of the Butajira
SMD cohort recruitment, additional people with SMD
living in the Butajira SMD/TaSCS recruitment area have
sought care from this clinic because they are (1) incident
cases, (2) missed cases from the original recruitment, or
(3) they have migrated into the area. If the TaSCS trial is
unable to recruit a sufficient sample size from the
Butajira SMD cohort, consecutive attendees at the Butajira
hospital psychiatric clinic will be screened for eligibility.
Recruitment into the trial will be divided into two
phases. In Phase 1, only people with SMD who are clin-
ically stable will be recruited. Three months after begin-
ning recruitment, the Data Safety and Monitoring Board
(DSMB) will review adverse events, including non-
engagement with the service, disengagement from care
and evidence of potentially dangerous prescribing, before
Phase 2 recruitment is permitted. In Phase 2, people
with SMD who have more complex needs or who are
clinically unstable will be recruited.
Eligibility criteria for both phases of recruitment
To be eligible, participants must meet the following criteria:
1. A Diagnostic and Statistical Manual of Disorders
(version IV) [38] diagnosis of schizophrenia,
schizoaffective disorder, bipolar disorder or major
depressive disorder made using a standardised,
semi-structured clinician-administered assessment.
2. Ongoing need for mental health care, defined as
active prescription of psychotropic medication or
prescription of psychotropic medication within the
preceding 2 years, or the person being in partial or
full relapse.... These severity criteria were developed
to reflect realities of service provision in Ethiopia: a
person with SMD who has been well off medication
for at least 2 years is unlikely to engage actively with
treatment services or be considered a priority by
PHC workers [39].
3. Not treated with a mood-stabiliser, second generation
antipsychotic medication or thioridazine (still used in
clinical practice in Ethiopia), as these medications are
not available routinely in the study area.
4. Living in the catchment area of one of the health
centres in the trial study site, excluding Butajira
health centre catchment area. Butajira health centre
is excluded because formative work indicated a
lower acceptability of randomization in those who
live in close proximity to the psychiatric nurse-led
unit in Butajira hospital [40].
5. Planning to continue living in the area for the
duration of the trial (at least 18 months).
6. The age criterion for recruitment into the original
Butajira SMD cohort was 18 years or older, but
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participants are now older than this in view of the
length of time that the cohort has been running.
Therefore, participants recruited from the Butajira
hospital psychiatric clinic will be required to be
25 years or above in order to ensure comparability.
7. Participants recruited from the Butajira hospital
psychiatric clinic will also be required to have been
in contact with mental health services for at least
2 years to ensure comparability with the Butajira
SMD cohort recruits.
8. Competent in the Amharic language. There is high
ethnic and linguistic diversity within the study site, but
the majority of people speak Amharic, the official
language of Ethiopia, even if it is not their first language.
9. Not expressing active suicidal intent.
10.Not receiving treatment for a co-morbid medical
condition at Butajira hospital.
11.Not pregnant while receiving depot medication.
12.Able to give informed consent or, if lacking capacity
to consent and no evidence of refusal, guardian
permission obtained.
Additional eligibility criteria for Phase 1
1. Not pregnant or breast-feeding.
2. No co-morbid complex or unstable medical
condition interfering with management of SMD.
3. Not fulfilling criteria for a diagnosis of alcohol or
khat use disorder in the past 12 months.
4. Not prescribed depot antipsychotic medication at
the time of assessment.
5. Stable clinical condition: either in remission from
SMD or with residual symptoms that have been
stable over the preceding three months.
6. No suicide attempt in the past three months.
7. Not restrained.
The eligibility criteria for the trial are designed to en-
sure that the findings can be generalised to people with
SMD in Ethiopia who will be receiving mental health
care integrated into PHC as part of the planned scale up
of mental health care by the Federal Ministry of Health.
The population will also be comparable to the Ethiopian
studies that have shown the psychiatric nurse-led care
(control arm) to be clinically effective [2, 41]. The opera-
tionalisation of eligibility criteria and their assessment is
detailed in Additional file 1.
Recruitment and screening
See Fig. 1.
Phase 1 (Butajira SMD cohort only)
Because the last formal assessment of all cohort partici-
pants was in 2011/2012, a process of pre-screening will
take place prior to starting recruitment into the trial. A
pre-screen will be completed from the project clinical re-
cords and in consultation with project outreach workers.
At this stage, people who are known to be prescribed psy-
chotropic medications that are unavailable outside of
Addis Ababa or who are taking depot medication, those
who are documented to be pregnant or breast-feeding and
those who are documented to have relapsed (within the
previous three months) will be excluded. These criteria
provide the sampling frame for Phase 1.
Each person with SMD included in the sampling frame
for Phase 1 will be ordered randomly using computerized
generation of random numbers. This random order will
form the sequence in which potentially eligible patients
will be invited for assessment by project outreach workers
who are well known to the patients and their families. At
the time of invitation, the project outreach workers will
also identify the appropriate caregiver to accompany the
patient to the baseline assessment. The recruitment and
assessment will take place at the mental health research
office in Butajira where there will be full access to the clin-
ical notes. The target sample size for Phase 1 is 124.
For people with SMD who attend a trial assessment, a
psychiatric nurse will conduct an assessment of capacity to
consent to participate in the trial. After obtaining informed
consent from the patient (if they have capacity) or permis-
sion from the guardian (if they lack capacity and are not
refusing to participate), the initial baseline assessment mea-
sures will be administered by psychiatric nurses. On the
basis of this initial assessment, eligibility for inclusion
within Phase 1 of the trial will be determined. All patients
who are eligible will then complete further assessments ad-
ministered by non-clinical data collectors. The caregiver of
the patient will also be invited to participate in the study,
their consent obtained and measures administered by non-
clinical data collectors. Once both patient and caregiver as-
sessments are complete, randomization will take place.
Phase 2 (Butajira SMD cohort and Butajira hospital
psychiatric clinic)
Phase 2 recruitment will be from the sampling frame of
the Butajira SMD cohort in the first instance, only pro-
gressing to the Butajira hospital psychiatric clinic if the
required sample size has not been reached.
(1)Butajira SMD cohort
Phase 2 recruitment will proceed as for Phase 1. Pre-
screening will only exclude women who are recorded as
being pregnant at the same time as being prescribed
depot and people who have already been recruited into
the trial. The target sample size for Phase 2 is 200.
(2)Butajira hospital psychiatric out-patient clinic
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If it is not possible to obtain the sample size for Phase
2 from the Butajira SMD cohort alone, we will expand
recruitment to the Butajira hospital out-patient clinic.
Unlike participants recruited from the Butajira SMD co-
hort, these recruits will not have undergone diagnostic
research assessments. This adds an additional step to the
recruitment process. Consecutive attendees who have a
clinical diagnosis of SMD (as defined previously) will be
pre-screened by the Butajira hospital psychiatric nurses.
If the person fulfils all of the pre-screening criteria, they
and their accompanying caregiver will be invited to meet
with the trial psychiatric nurse who will evaluate the
capacity of the person to consent to participate in the
trial. If the person has capacity and gives informed con-
sent or the eligible caregiver gives permission, they will
be undergo a standardised, semi-structured diagnostic
evaluation by a mental health professional [35, 42]. If the
person fulfils criteria for DSM-IV diagnoses of schizo-
phrenia, schizoaffective disorder, bipolar disorder or
depressive disorder, they will be invited to return to the
Butajira mental health research office on a convenient
date when they can undergo the full screening and base-
line assessment accompanied by an eligible caregiver.
Randomisation and service allocation
Sequence generation and allocation concealment
A computerized system will be used to generate a
randomization list. The randomization will be stratified
by health centre catchment area. Within each health
centre catchment area, randomization will be organized
with permuted blocks of random size so that an equal
number will be randomized to the new intervention arm
and to the active control arm. From the randomization
list, labelled and sealed envelopes will be prepared con-
taining cards with intervention allocation. The sealed en-
velopes will be handed over to independent clinicians
working in Butajira hospital and will be kept in a secure
place.
Fig. 1 Flow chart of the Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (TaSCS) trial
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Intervention allocation
Upon completion of the baseline assessment, participants
will be accompanied to Butajira hospital. In a fully private
location, the independent clinician will open the next se-
quential envelope for the health centre catchment area
where the person resides and inform the participant of the
service to which they have been allocated (that is, psychi-
atric nurse-led care or care from the health centre staff ).
Masking
Outcome assessors and trial investigators will be masked
to the intervention allocation of participants, but it is
not possible for trial participants and clinicians involved
in delivering the intervention service to be masked. To
minimise the possibility of unmasking of outcome asses-
sors, 1) outcome assessments will be carried out by
project-employed mental health professionals and lay in-
terviewers in a location that is independent of and geo-
graphically separated from the health service; 2) the
outcome assessors will not work in the trial districts; 3)
when patients and caregivers are registered for their
follow-up assessments, they will be instructed not to tell
the interviewer where they are receiving mental health
care; 4) selected trial clinical assessments will be ob-
served by non-project psychiatrists to ensure that ratings
are being conducted without bias; and 5) at the end of
each follow-up assessment, the assessor will be asked
whether they have become unmasked to patient alloca-
tion group during the course of the assessment. This in-
formation will be used to conduct a sensitivity analysis
to investigate any evidence of bias. Data analysis for the
primary outcome will be carried out by an independent
organization, and those involved in data analysis will be
masked to the intervention status of the participant.
Interventions
Intervention arm
The intervention is a task sharing model of mental
health care for people with SMD integrated into PHC,
as recommended by the WHO in the mental health Gap
Action Programme (mhGAP) [21] and endorsed by the
Ethiopian Federal Ministry of Health [16]. Adaptation of
the task-sharing model for the study setting was in-
formed by extensive formative work and community
consultation in the study site [40] and from findings
arising from a sister project implementing integrated
mental health care in a neighbouring district [43, 44].
In the TaSCS intervention, PHC-based health centre
nurses and health officers will be trained to deliver the
mhGAP packages of mental health care, supported by
community-based health extension workers. The train-
ing and supervision requirements are summarised in
Table 1. As all trial participants have an existing care
plan used by project psychiatric unit staff, this will be
transferred to PHC when a patient has been randomised
to a PHC site. A minimum of monthly, facility-based
follow-ups will be stipulated during the initial phase, and
thereafter, 3-monthly follow-ups, although contacts can
be more frequent depending on patient need. The
current outreach by project workers will be replaced by
outreach by health extension workers, who are required
to make house-to-house visits every 3 months, as part of
Table 1 Task sharing intervention for the Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (TaSCS) trial
Recipients Intervention
Training Ongoing support and structures
Health centre nurses and
health officers
9 days of training in mhGAP-IG packages (4 days of base
course + 5 days of on-the-job training)
Phase I: Support and supervision by project psychiatric nurse
tapering down from weekly to bi-weekly
Delivered by project psychiatric nurse supported by
project psychiatrist
Phase 2 onwards: Monthly support and supervision by project
psychiatric nurse
Pre-study run-in phase: on-the-job training with patients
with SMD who volunteer for treatment in PHC, delivered
by project psychiatric nurse
Supervision sessions will include discussion of all cases
presenting with suicidal ideation or a psychiatric emergency,
discussion of complex cases, developing supportive
relationships with the general health care provider and
trouble-shooting.
1-day refresher training at 6 and 12 months Emergency consultation with project psychiatric nurse
Referral for specialist review at Butajira psychiatric unit
Register of appointment times for persons with Severe Mental
Disorder needing ongoing care
Health extension workers 2-day training course based on Ministry of Health
training materials*.
Monthly supervision by health centre-based supervisor
Delivered by project psychiatrist Consultation with health centre supervisors
District health office and
community stakeholders
Stakeholder workshop facilitated by project psychiatrists Regular meetings of the trial advisory board and one-to-one
liaison of project psychiatric nurse with district health office
heads
* http://www.open.edu/openlearnworks/course/view.php?id=19%3f
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their health promotion and illness prevention responsi-
bilities. Psychiatric nurse-led mental health support will
be provided to the PHC health officers and nurses
through (1) supervision including case reviews, discussion
of difficult cases, developing supportive relationships with
the primary health care provider and trouble-shooting; (2)
emergency consultation with project psychiatric nurses;
and (3) referral for a second opinion or for a period of
follow-up by the specialist team in Butajira psychiatric
unit, as per mhGAP guidelines. Psychiatric nurses can in
turn consult project psychiatrists. The roles of the PHC
workers in the task shared model are summarised in
Additional file 2.
Active comparison arm
The active comparison sample for the TaSCS trial is a
psychiatric nurse-led, centralised model of out-patient
specialist mental health care augmented by commu-
nity outreach by lay workers as part of the Butajira
SMD study. There are 57 psychiatric nurse-led units
across Ethiopia providing the lion’s share of specialist
mental health care in the country [37]. Psychiatric
nurse-led clinics constitute the only model of mental
health care available in rural areas in Ethiopia. The
comparison arm of the TaSCS trial can be considered
to be an enhanced version of specialist mental health
care, in that community outreach is provided. Evalu-
ation of the longitudinal illness course of patients in
the Butajira SMD study showed improved outcomes
for those who engaged with the service compared to
those who did not engage [2].
The Butajira hospital psychiatric nurses are able to
prescribe psychotropic medication (including depot anti-
psychotic medication), monitor and intervene against
side effects, diagnose co-morbid psychiatric conditions
and provide simple psychosocial interventions. Follow
up will be arranged on the basis of need, but at least a
face-to-face assessment every three months. Consult-
ation with project psychiatrists or referral for in-patient
psychiatric care (in Addis Ababa) will be as indicated.
The psychiatric nurses will receive 2 days of refresher
training in order to familiarise them with the WHO’s
evidence-based guidelines for management of mental
disorders (mhGAP-IG). They will also receive refresher
training on the management of SMD in pregnant and
breastfeeding women.
Fidelity
The competence of the PHC workers to deliver mental
health care will be evaluated through pre- and post-
training assessments of knowledge and attitudes [45] to-
wards mental health, post-training evaluation of clinical
skills [46] and structured supervision reports from the
project psychiatric nurses. The fidelity of the task shared
mental health care to the mhGAP intervention packages
will be measured through structured evaluation of clin-
ical follow-up forms by independent psychiatrists, in-
cluding prescribing, risk assessment, psychoeducation
and symptom review. Medication is being supplied by
the trial, but a record will be kept of any interruptions
to supply.
The fidelity of the active comparison specialist mental
health care model to evidence-based mental health care
will be measured through structured evaluation of clin-
ical follow-up forms by independent psychiatrists, as for
the intervention arm.
Outcomes
The trial outcomes are summarised in Table 2.
Primary outcome
The primary outcome is non-inferior symptom level, de-
fined as no more than a six-point higher mean score on
the BPRS-E [47]. The BPRS-E is a 24-item, clinician-
rated scale that was originally developed for detection of
symptom change in persons with persistent SMD [47].
Each item is rated on a scale from 1 to 7 (1 = not
present; 2 = very mild; 3 =mild; 4 =moderate; 5 = moder-
ately severe; 6 = severe and 7 = extremely severe). The
maximum total score is 168. The BRPS-E focuses on
symptoms of psychosis but also has items covering the
symptom domains of somatic concerns, anxiety, depres-
sion and mania. The total BPRS-E score is sensitive to
change in treated in-patient populations of persons with
persistent SMD, including those with diagnoses of
schizophrenia, bipolar disorder and major depressive
disorder [48]. The BPRS-E has also been used in treat-
ment trials with out-patient populations of persons with
SMD [49, 50] and has been used in Ethiopia previously
[51]. The factor structure and sensitivity to change of
the BPRS-E has been shown not to vary significantly
across diagnostic groups [48]. Inter-rater and test-retest
reliability, as well as internal consistency, have been
shown to be high [52].
The non-inferiority margin for the primary outcome
needs to be defined in relation the minimal clinically im-
portant difference (MCID) [53]. Previous studies have
defined clinically significant change in score on the
BPRS-E in different ways. Using a statistical approach,
the ‘reliable change index’ [54] for change in BPRS-E
score from beginning to end of an in-patient admission
in persons with SMD equated to 18 points [55]. How-
ever, change in symptoms in a person with acute psych-
osis receiving in-patient care is likely to be larger than
the MCID and not applicable to the out-patient sample
of people with SMD to be included within this sample.
In a study looking at change in symptoms in response to
a psychological intervention for an out-patient sample of
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people with chronically symptomatic schizophrenia, a
mean change of 7.9 points on the BPRS-E was consid-
ered clinically important [49]. A mean change of 7.9
points equates to a standardised effect size of around
0.50, which we take to be the MCID. In line with recom-
mendations for non-inferiority trials, the non-inferiority
margin for this trial will be 75 % of the presumed MCID,
that is, a six-point difference in mean BPRS-E scores
between arms of the trial [53, 56]. A six-point difference
on the BPRS-E equates to a standardised effect size of
0.4.
Secondary outcomes
See Table 2.
A wide range of secondary outcomes are being
assessed in view of the importance of exploring the full
Table 2 Summary of outcomes measures for the Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
(TaSCS) trial
Outcome Measure Timing
Primary outcome
1 SMD symptom severity BPRS-E Baseline, 12* and 18 months
Secondary outcomes
1. Functional impairment± WHODAS 2.0 (12-item) Baseline, 12 and 18 months
Local functioning scale Baseline, 12 and 18 months
2. Relapse of mental disorder LCS Baseline, 12 and 18 months
3. Service use costs CSRI Baseline, 12 and 18 months
4. Satisfaction with mental health
care
Mental health service satisfaction scale (MHSSS) Baseline, 12 and 18 months
Qualitative in-depth interviews From 6 months post-randomisation
5. Nutritional status Body Mass Index Baseline, 12 and 18 months
6. Service use for physical health
conditions
CSRI Baseline, 12 and 18 months
7. Medication side effects ASC Baseline, 12 and 18 months
8 Patient engagement and
adherence
Medication Adherence Measure Clinic attendance Baseline, 12 and 18 months
9. Perceived stigma ISMI Baseline, 12 and 18 months
10. Restraint± Proportion chained, restrained or confined in last month Baseline, 12 and 18 months
11. Quality of care Document review Monthly for 3 months, 6, 12 and
18 months
13. Adverse events (AEs) LCS and project reporting mechanisms for AEs Continuous for serious AEs 6-monthly
for other AEs
Mediating variable
1. Therapeutic alliance HAQ Baseline, 12 and 18 months
Caregiver outcomes
1. Perceived stigma FIS Baseline, 12 and 18 months
2. Caregiver burden FIS Baseline, 12 and 18 months
3. Time burden of caring and
opportunity costs
CSRI Baseline, 12 and 18 months
Potential confounding variables
1. Sociodemographic characteristics Structured self-report of age, sex and marital status Baseline
2. Socio-economic status Structured self-report of educational level, occupational status, food
insecurity and family size
Baseline
3. Alcohol use disorder FAST Baseline
4. Khat use disorder CIDI substance use module Baseline
5. Medical co-morbidity or physical
disability
Structured self-report Baseline
* Primary outcome; ± proxy version also administered to caregivers. BPRS-E, Brief Psychiatric Rating Scale, expanded version [6, 60]; WHODAS 2.0, World Health
Organisation Disability Assessment Schedule, Version 2.0 [61]; LCS, Life Chart Schedule [62]; CSRI, Client Service Receipt Inventory [63, 64]; ASC, Antipsychotic Side
Effect Checklist [65], Medication Adherence Measure [66]; ISMI, Internalised Stigma of Mental Illness [67]; HAQ, Helping Alliance Questionnaire [68]; FIS, Family
Interview Schedule [69]; FAST, Fast Alcohol Screening Test [70]; CIDI, Composite International Diagnostic Interview [33]
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range of possible harms when conducting a non-
inferiority trial. The secondary outcomes are functional
impairment, relapse of SMD, service use costs, satisfac-
tion with mental health care, nutritional status, service
use for physical health conditions, disengagement from
care, non-adherence with medication, experience of side
effects, perceived stigma, experience of being restrained,
quality of care and adverse events. Caregiver outcomes
are perceived stigma, family burden, time burden and
opportunity costs of care giving.
Potential confounders
In order to be able to adjust for potential confounding
in case of randomly unequal distribution of variables,
baseline measurement of the following variables will be
carried out: socio-demographic characteristics, socio-
economic status, alcohol use disorder, khat use disorder
and medical co-morbidity and physical disability. See
Table 2.
Sample size calculation
The following formula was used to calculate the re-
quired sample size (n):
n ¼ 2 σ=Δ½ 2 Zα þ Zβ
 2
;
where delta = non-inferiority margin (mean BPRS-E
scores of six points), sigma is the standard deviation of
the BPRS-E score (estimated standard deviation of 15
[57]), Zalpha is the standardised mean difference for the
probability of type 1 error (alpha = 0.05) and Zbeta is the
standardised mean difference for the probability of type
2 error (beta =0.1 (that is, power of 0.9). Therefore, a
sample size of 107 persons per arm of the trial (that is, a
total of 214) is required [58]. No published studies from
Ethiopia are available to guide us in our estimation of
the intra-cluster correlation (ICC) for study subjects re-
ceiving treatment from a specific health centre. We
therefore estimate the ICC to be 0.01, which is the me-
dian ICC from a review of 31 cluster-based interventions
in PHC [59]. Given that there are 13 health centres
within the three districts covered by the Ethiopia TaSCS
trial, the design effect will be 1 + (n-1)*ICC (where n =
number of subjects per cluster). Therefore, the design
effect = 1 + (17–1)*0.01 = 1.16. Assuming a worst-case
scenario of 30 % loss to follow-up, the required sample
size = 214 * 1.30 * 1.16 = 323 participants. For equal
numbers in each arm of the trial, the total sample size
will be 324 (n = 162 in each arm).
Data management and analysis
Data management
A data management plan was developed to specify all
procedures relating to the handling of trial data.
Management of data for the masked outcome data will
be handled by the Clinical Trials Unit at the Armauer
Hanssen Research Institute (AHRI) with support from
the trial statisticians. Data will be doubled entered from
the Patient Report Forms into an electronic Case Report
Form. Trial data with unmasking potential (process data
and data pertaining to adverse events) will be handled
by the Butajira mental health research office following
the same standardised operating procedures as for the
Clinical Trials Unit. Data cleaning based on frequency
distributions and logic checks will follow standard pro-
cedures with reference to source documents as required.
Data analysis approach
Data analysis will follow a detailed statistical analysis
plan that specifies all planned analyses. Data analysis will
take place using Stata Version 13 (Stata Corporation,
College Station, Texas, USA) under the direction of the
trial statisticians. All analyses will be masked to study arm
until the analysis is finalized and approved by all investiga-
tors. Descriptive analyses will include frequency distribu-
tions and measures of central tendency and dispersion, as
appropriate, with 95 % confidence intervals. Bivariable
comparisons will employ χ2, Fisher’s exact, Student’s t- or
rank-sum tests, as appropriate. All statistical tests will be
one-sided at α = 0.05, as we are testing a hypothesis of
non-inferiority and not superiority or equivalence.
Analysis will be by intention-to-treat, that is, on the
basis of the group to which the participant is allocated
randomly at the beginning of the trial. Intention-to-treat
has the potential to lead to false acceptance of the hy-
pothesis of non-inferiority in the presence of a true dif-
ference if there is a large cross-over from the primary
care to the psychiatric nurse service [60]. Therefore, the
intention-to-treat analysis will be presented together
with the percentage of participants who deviate from the
protocol in the following ways: (1) cross-over protocol
deviation which is indicated by the percentage who at-
tend for more than two consecutive visits at the service
they were not randomised to receive, unless they were
referred to that service, and (2) disengagement from care
protocol deviation, which is the percentage who miss
more than 50 % of their scheduled health facility appoint-
ments (not attending within 2 weeks of the appointment
date). Per protocol analyses will also be conducted, and
the findings presented as a sensitivity analysis. Account
will be taken of clustering at the level of the health facility.
Analysis will be carried out on the complete data set at
12 and 18 months. For the primary outcome time-point of
12 months, it would not be appropriate to carry forward
the last observation to replace missing data as this would
have taken place at the baseline of the study and could,
therefore, increase the chance of non-inferiority even in the
presence of a difference between the allocated services.
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If more than 15 % of the primary outcome scores are
missing, we will conduct multiple imputation analysis
(including age, sex, baseline symptom severity and sub-
stance use disorder) in the model and present this as an
exploratory analysis alongside the analysis on the
complete dataset.
Interim analysis
An interim analysis will be conducted at 12 months. The
DSMB will assess the primary outcome (BPRS-E score)
and adverse events by arm of the trial and decide if there
is evidence of inferiority of one arm, guided by the defin-
ition of clinical inferiority used for the primary hypothesis.
Analysis of primary outcome
The analysis for the primary outcome will be carried out
by AHRI in order to ensure masking of the treatment
group. The primary outcome measure (change in BPRS-E
score) will be analysed using linear regression adjusting
for baseline symptom severity. Statistical tests will be one-
sided, reflecting our interest in testing the hypothesis that
task-shared care is non-inferior. The validity of regression
assumptions will be checked using residual plots. For the
purpose of safety monitoring, the Phase 1 primary out-
come at 12 months will be analysed as an interim analysis.
For the purpose of hypothesis-testing for the main trial,
Phase 1 and Phase 2 primary outcomes at 12 months will
be combined. Both crude and adjusted (for baseline symp-
tom severity, age and sex) effect sizes will be presented for
the primary analysis. Exploratory analysis of the non-
inferiority of the new intervention in the Phase 1 and
Phase 2 participants will be carried out separately.
Analysis of secondary outcomes
These analyses will be carried out by the trial statisticians.
The planned approach for data analysis of secondary out-
comes is outlined in Additional file 3. Multivariable ana-
lysis will be used to adjust for the following potential
confounding variables measured at baseline: age, sex, so-
cioeconomic status, substance use and symptom severity.
Economic analysis
The economic analysis will measure both the costs asso-
ciated with a task-sharing model of care, as well as the
consequential impact on service use. Local unit costs
will be applied to resources used so as to estimate
changes in services costs in both intervention and com-
parator groups. Time lost from work by people with
SMD and their caregivers will be valued using appropri-
ate wage rates, adjusted to take account of patterns of
employment in an agrarian economy. Costs will be ana-
lysed using multiple regression analysis so that the effect
of the intervention on costs can be estimated whilst
adjusting for differences in participant characteristics.
Non-parametric bootstrap methods will be used if the
residuals of the regression model are non-normally dis-
tributed. Further regression models will include the
main clinical measures so that the relationship between
costs and outcomes can be assessed. A cost-effectiveness
analysis will be carried out. Differences in cost and pri-
mary outcome measure (BPRS-E) that take into account
the uncertainty around point estimates will be plotted
and subsequently presented as a cost-effectiveness ac-
ceptability curve.
Ethical considerations
Ethical approval for the trial has been obtained from the
Institutional Review Board of the College of Health Sciences,
Addis Ababa University (Reference Number 030/12/Psy),
the AHRI-ALERT Ethics Review Committee (Reference
Number P037/13), the National Research Ethics Review
Committee of Ethiopia (Reference Number 3.10/758/07),
the Food, Medicine and Health Care Administration and
Control Authority (Reference Number 02/6/22/13), the
University of Cape Town Human Research Ethics Commit-
tee (Reference Number 226/2011) and the National Insti-
tute of Mental Health Data Safety and Monitoring Board
(DSMB).
The trial will include people with SMD who lack cap-
acity to consent to participate in the trial as long as they
are not actively refusing and they have a guardian who
gives permission. Given the lack of knowledge on task-
sharing care for people with SMD, and the intention of
the Ethiopian Ministry of Health to implement this new
model of service provision, it is crucial that people with
SMD who are representative of those who will receive the
task sharing model in the future have the opportunity to
participate in the study. In participants who lack capacity
at baseline, the capacity to consent will be reviewed at
follow-up assessment time-points. If the participant
regains capacity, they will be informed about the trial and
will only continue in the trial if they give informed con-
sent. No out-patient treatment from non-specialist mental
health workers will be provided to people with any mental
disorder against their will, except for management of
acute behavioural disturbance where the person poses an
imminent risk to themselves or others.
There is genuine uncertainty as to whether or not a
task-sharing model of mental health care for SMD can
be as effective as mental health care delivered by mental
health specialists, but also no evidence that it is any
worse, supporting a position of clinical equipoise. In the
absence of any difference in effectiveness of care, a task-
sharing model of care may be preferred through being
locally available, even if the practitioners delivering the
care are not specialists.
During the trial period participants will directly benefit
from free treatment for both mental and physical health
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problems. Participants will be compensated for transport
and their time when attending for trial-related assess-
ments. Transport costs for attending Butajira hospital
will also be covered.
We anticipate that the main risks for those allocated
to the task-sharing model of mental health care in PHC
will be modest: 1) moving from a familiar arrangement
to a new treatment setting may be unsettling at the be-
ginning, and therefore, monthly reviews will be sched-
uled at the beginning of the trial in order to facilitate
engagement; and 2) there is a risk of receiving inferior
care, which will be detected through monitoring of clin-
ical records, supervision and the 12 month interim ana-
lysis. It is not anticipated that either arm of the trial will
be associated with an increase in serious or other adverse
events; however, procedures are in place for minimising
the risk of adverse events and ensuring monitoring,
reporting and management of adverse events to the
DSMB and other regulatory bodies. The risk of suicide
will be minimised by excluding people who express active
suicidal intent at the time of recruitment and requiring
clinicians to use structured clinical follow-up forms that
prompt for screening for suicide risk. The phased nature
of recruitment is also designed to reduce risk of adverse
events by ensuring that PHC workers have gained compe-
tence in managing care of people with stable or uncompli-
cated SMD before they take on the care of people with
more complex illness. The occurrence of serious or other
adverse events will be formally reviewed at 12 months as
part of the interim analysis.
All trial-related assessments will take place in a loca-
tion that respects the participant’s privacy. The confi-
dentiality of the participants will be respected, and the
names of the patients will not be quoted or published.
The trial will be subjected to rigorous on-site monitor-
ing of safety and quality at study initiation and thereafter
twice per year by an independent external monitor
reporting to the NIMH DSMB, in addition to routine
reporting to the NIMH DSMB twice per year.
Discussion
A pressing need exists to scale up evidence-based pack-
ages of mental health care in LMICs and thereby im-
prove the clinical, functional and social outcomes of
people with mental disorders. Alongside this imperative
runs a critical need to evaluate the success of the task-
sharing models of mental health care, which are pro-
posed as solutions to the treatment gap for mental disor-
ders. Human resource and health system constraints
mean that interventions that are demonstrated to be effi-
cacious when evaluated individually cannot be assumed
to be effective when delivered as part of a service in
more real-world conditions. The dearth of high-quality
mental health service trials from LMICs generally, and
from low-income countries in particular, is a serious im-
pediment to the successful scale-up of mental health
care. The TaSCS trial seeks to provide high-quality evi-
dence that will be timely for informing mental health
care scale-up in other rural, low-income countries, as
well as contributing to the international discourse on
task sharing as an acceptable model of care for people
with SMD.
Trial status
Recruitment started on 13 March 2015 and is ongoing.
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